Rigel focuses on discoid lupus erythematosus drug, discontinues development as RA treatment

Rigel Pharmaceuticals has announced plans to focus its resources on three lead clinical programs, including a topical dermatological JAK/SYK inhibitor for discoid lupus erythematosus.The San Francisco-based company will discontinue development of fostamatinib, an oral SYK inhibitor, for treating rheumatoid arthritis or lymphoma because of insufficient efficacy findings in recent clinical trials, as well as “the competitive landscape for the agent in these indications,” according to a press release.

Full Story →